IDiyas

For the Inventor, By the Inventor

Bloomington, IN, United States of America

Mark Alan Richardson

USPTO Granted Patents = 7

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 21(Granted Patents)


Company Filing History:

goldMedal7 out of 4,443 
 
Eli Lilly and Company
 patents

Years Active: 1998-1999

Loading Chart...
7 patents (USPTO):Explore Patents
1. 5980938 - Effect of compounds that suppress induction of plasminogen activator (1999-11-09),
2. 5962698 - Benzothiophene compounds, and uses and formulations thereof (1999-10-05),
3. 5948795 - Benzothiopene compounds, and uses and formulations thereof (1999-09-07),
4. 5945320 - Platenolide synthase gene (1999-08-31),
5. 5792798 - Method for inhibiting plasminogen activator inhibitor 1 (1998-08-11),
6. 5780648 - Benzothiophene compounds, and uses formulations thereof (1998-07-14),
7. 5731328 - Methods of inhibiting plasminogen activator inhibitor 1 (1998-03-24),

Title: Mark Alan Richardson: Innovator in Pharmaceutical Chemistry

Introduction

Mark Alan Richardson is a distinguished inventor based in Bloomington, IN (US). He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 7 patents. His work focuses on innovative methods and compounds that have the potential to impact medical treatments.

Latest Patents

Among his latest patents, Richardson has developed methods for inhibiting PAI-1 using benzopyrans. This invention provides valuable insights into the effect of compounds that suppress the induction of plasminogen activator. Additionally, he has introduced novel benzothiophenes and their intermediates, along with their uses and formulations, which are crucial for advancing therapeutic applications.

Career Highlights

Richardson is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His role at Eli Lilly allows him to collaborate with other experts in the field and contribute to groundbreaking research and development.

Collaborations

Throughout his career, Richardson has worked alongside notable colleagues such as David Thompson Berg and Brian W Grinnell. These collaborations have fostered an environment of innovation and have led to the successful development of various pharmaceutical solutions.

Conclusion

Mark Alan Richardson's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in the medical field. His patents and collaborative efforts continue to pave the way for advancements in treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…